Skip to main content

Clinical Prior Authorization Criteria for Androgenic Agents Will Be Revised February 1, 2023

Last updated on

On February 1, 2023, the Texas Health and Human Services Commission (HHSC) will revise the clinical prior authorization criteria for androgenic agents to comply with Section 1557 of the civil rights provision of the Affordable Care Act (ACA). The ACA prohibits discrimination based on race, color, national origin, sex, disability, or age in covered health programs and activities. HHSC will revise the criteria for approval by removing step 2, which checks for the gender of the client.

This clinical prior authorization is optional for managed care. MCOs that implemented it must revise the criteria by February 1, 2023.

Email vdp-formulary@hhsc.state.tx.us with comments or any questions.